secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0000914475-23-000072
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q3 INGREZZA sales $486M (+29% YoY); raises 2023 guidance to $1.82-1.84B
--------------------------------------------------------------------------------

- INGREZZA Q3 net sales $486M (+29% YoY); total product sales $492M.
- GAAP EPS $0.82; non-GAAP EPS $1.54. Cash & securities $1.55B.
- INGREZZA 2023 net sales guidance raised to $1.82-1.84B.
- FDA approved INGREZZA for Huntington's chorea; NDA accepted for oral granules (PDUFA Apr 30, 2024).
- Phase 3 crinecerfont met primary endpoints in adult and pediatric CAH; Analyst Day Dec 5.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000072/0000914475-23-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000072/nbix-20231031.htm
  HTML page:      https://secwatch.observer/filing/0000914475-23-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer